Bengaluru: The U.S. Food and Drug Administration (USFDA) is investigating the death of a child who developed dangerous antibodies after getting Takeda Pharmaceuticals’ Adzynma therapy for a rare blood disorder, raising alarm over potential life-threatening outcomes of the drug.
The agency is also evaluating whether additional regulatory action is needed.
“We reported this event to the U.S. Food and Drug Administration and have been providing them with updates since we became aware in July”, a Takeda spokesperson said in an email to Reuters.
The company has also conducted a thorough assessment and determined that there was no confirmed causal relationship to the use of Adzynma and the patient death, the spokesperson added.
The pediatric patient with cTTP had neurologic symptoms that progressed and developed antibodies that blocked the activity of ADAMTS13. The death occurred about 10 months after starting Takeda’s therapy. Before beginning treatment with Adzynma, the patient had previously experienced severe allergic reactions to fresh frozen plasma, which is a traditional treatment for the condition.
The FDA said it has received multiple postmarketing reports of patients developing such antibodies after treatment with Adzynma, though these were not observed during clinical trials.
While the current prescribing information warns about the potential risk of antibody development, it does not include details about postmarketing cases involving serious or fatal outcomes.
